Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026
Agenus presented Phase 2 data for its BOT+BAL combination in advanced melanoma patients refractory to prior checkpoint therapy. In the overall cohort of 36 heavily pretreated patients, median overall survival was 16.6 months, with 42% alive at two years and a 22% confirmed objective response rate. Responses were highly durable, with 86% of responders remaining in response at 12 months. In the dual-refractory subgroup, median survival was not reached and 64% were alive at two years.
Key figures
- Drug Name
- botensilimab (BOT) + balstilimab (BAL)
- Phase Of Trial
- Phase 2
- Orrr pct
- 22
- N patients
- 36
- Os 2yr rate pct
- 42
- Median os months
- 16.6
- Grade3 plus ae pct
- 36
- Dual refractory orrr pct
- 29
- Durable response 12mo pct
- 86
- Dual refractory os 2yr pct
- 64
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.